A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 48/00 (2006.01) A61K 38/17 (2006.01) A61P 25/14 (2006.01) C12N 5/00 (2006.01) C12N 15/67 (2006.01) C12Q 1/18 (2006.01) C12Q 1/68 (2006.01) C07K 14/47 (2006.01) C07K 14/705 (2006.01) C12N 9/64 (2006.01)
Patent
CA 2609695
Use of ubiquilin is described, including utilization for reducing fragmentation of presenilin 1 and 2 and to modulate .gamma.-secretase components, Pen-2 and Nicastrin, as well as utilization for inducing increased levels of ubiquilin to reduce aggregation of polyglutamine expansion proteins known to cause cell toxicity and cell death in subjects suffering from neurodegenerative diseases, such as Huntington's and Alzheimer's diseases.
La présente invention concerne l'utilisation de l'ubiquiline. Cette invention est utilisée pour réduire la fragmentation de préséniline 1 et 2 et pour moduler des composants .gamma.-sécrétase, Pen-2 et Nicastrine, ainsi que pour induire une augmentation des niveaux d'ubiquiline afin de réduire l'agrégation de protéines d'expansion de polyglutamine qui sont connues pour causer la toxicité cellulaire et la mort cellulaire chez des sujets souffrant de maladies neurodégénératives telles que la maladie de Huntington et la maladie d'Alzheimer.
Monteiro Mervyn J.
Wang Hongmin
Gowling Lafleur Henderson Llp
University Of Maryland Biotechnology Institute Off. Of Research
LandOfFree
Ubiquilin regulation of presenilin endoproteolysis, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ubiquilin regulation of presenilin endoproteolysis, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ubiquilin regulation of presenilin endoproteolysis, and... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1360357